Corcept Therapeutics, based in Menlo Park, California, is a commercial-stage pharmaceutical company that markets Korlym for Cushing's syndrome and has a portfolio of selective cortisol modulators. Founded in 2004, it employs 352 people and offers around 1,000 compounds.
Corcept Therapeutics (CORT) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Corcept Therapeutics's actual EPS was $0.29, beating the estimate of $0.19 per share, resulting in a 51.59% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
